



Contact:

Douglas Doerfler
Chief Executive Officer
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte to Be Featured at the BIO CEO & Investor Conference

Gaithersburg, MD, February 18, 2005 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announced Douglas A. Doerfler, President and CEO, will be presenting at the BIO CEO & Investor Conference in New York City, The Waldorf-Astoria Hotel, Park Ave Suite Center/North Room on Wednesday, February 23, 2005, at 12:00PM EST.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product candidates, partnering activities, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte is a clinical stage therapeutics company developing both proprietary and partnered therapeutics. The company's mission is to use its proprietary cell-loading technology to advance its therapeutic programs and enable other developers of ex vivo cell therapies and manufacturers of biopharmaceutical products and therapies. MaxCyte's strength is its ability to accelerate development timelines and reduce risk in bringing cell and gene therapies from bench to a clinical reality. MaxCyte's proprietary cell loading technology is closed and scalable, highly efficient, reproducible and reduces regulatory risk in *ex vivo* cell loading. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. Therapeutic applications include non-viral gene delivery and delivery of a therapeutic drug or large proteins; current partners are working to develop therapeutics for pulmonary disease and oncology. MaxCyte's technology for biotherapeutic manufacturing allows the scalable production of viral vectors, making possible all phases of the development process, from pre-clinical through clinical trials and through to product manufacturing. Cell-loading technologies are fundamental to cell-based therapeutics, gene therapy, and many biopharmaceutical manufacturing applications. MaxCyte has developed and commercialized the most efficient non-viral, clinical grade, scaleable, GMP-compliant cell-loading technology in the marketplace.

For more information including the referenced abstract, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###